TAE226 (NVP-TAE226)

Catalog No.S2820

For research use only.

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.

TAE226 (NVP-TAE226) Chemical Structure

CAS No. 761437-28-9

Selleck's TAE226 (NVP-TAE226) has been cited by 21 publications

Purity & Quality Control

Choose Selective FAK Inhibitors

Other FAK Products

Biological Activity

Description TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.
PYK2 [1]
(cell-free assay)
FAK [1]
(cell-free assay)
Insulin Receptor [1]
(cell-free assay)
IGF-1R [1]
(cell-free assay)
c-Met [1]
(cell-free assay)
Click to View More Targets
3.5 nM 5.5 nM 43.5 nM 140 nM 160 nM
In vitro

NVP-TAE226 (< 1 μM) inhibits extracellular matrix-induced autophosphorylation of FAK (Tyr397) in serum-starved U87 cells. NVP-TAE226 (< 1 μM) also inhibits IGF-I-induced phosphorylation of IGF-1R and activity of its downstream target genes such as MAPK and Akt in both U87 and U251 cells. NVP-TAE226 (<10 μM) retards tumor cell growth and attenuats G(2)-M cell cycle progression associated with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression in both U87 and U251 cells. NVP-TAE226 (1 μM) inhibits tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay in glioma cell lines. NVP-TAE226 (1 μM) treatment of glioma cell lines containing wild-type p53 mainly exhibits G(2)-M arrest, whereas glioma cell lines bearing mutant p53 undergoes apoptosis, as evidence by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay. [1] NVP-TAE226 (5 μM) inhibits phosphorylation of FAK in the human neuroblastoma cell line SK-N-AS. NVP-TAE226 (<10 μM) treatment of the human neuroblastoma cell line SK-N-AS leads to decrease in cellular viability, cell cycle arrest, and an increase in apoptosis. [2] NVP-TAE226 (0.1 μM-10 μM) inhibits tube formation of HMEC1 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 cells MV;Qdo9tcW[ncnH0bY9vKGG|c3H5 MUm0PEBp NXXMdVNoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVAvPCEQvF2= NF7EOmYzPTF6ME[1OC=>
HUVEC NEfGTXdHfW6ldHnvckBie3OjeR?= NE\FXog4OiCq MXrBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKF[HR1[td5RqdXWuYYTl[EBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OD1zIN88US=> NIXTVWwzOzh2NUKxOy=>
U87MG cells M1j6[nBzd2yrZnXyZZRqd25iYYPzZZk> MkDFOFghcA>? MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6N13HJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OD1zLkKg{txO M2nvfVI2OThyNkW0
PC3 cells NVjPWYxXWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHXTbYs1QCCq Mki2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR|UxRTFwNjFOwG0> MXeyOVE5ODZ3NB?=
MDA-MB-231 cells MlPhVJJwdGmoZYLheIlwdiCjc4PhfS=> NVrFSldlPDhiaB?= NEHDfpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR|UxRTJwODFOwG0> NEGxb2QzPTF6ME[1OC=>
BT474 cells M2\0VGZ2dmO2aX;uJIF{e2G7 MVexJO69VQ>? NX;tVIhIOjRiaB?= M{nYNGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQmS0O|Qh[2WubIOgZZN{\XO|ZXSgZZMh[2ynYY\h[4Uhd2ZiOEmgb2RiKFCDUmCgZZQhOSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0eIlv\w>? MVqxPFk5QTl3MB?=
Methods Test Index PMID
Western blot FAK / p-FAK(Y397) / p-AKT(S473) / AKT / pERK / ERK 31215459
Growth inhibition assay Cell viability 21196322
In vivo NVP-TAE226 (75 mg/kg) significantly increases the survival rate of mice bearing intracranial glioma xenografts. [1] NVP-TAE226 (100 mg/kg, oral) exerts significant decrease in microvessel density in a human colon cancer model in SCID mice. [3] NVP-TAE226 (100 mg/kg, oral) efficiently inhibits MIA PaCa-2 human pancreatic tumor growth without body weight loss in vivo model. [4] NVP-TAE226 inhibits 4T1 murine breast tumor growth and metastasis to the lung in a dose-dependent manner in vivo model, associated with inhibition of FAK autophosphorylation at Y397 and Akt phosphorylation at Serine473. [5]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: U87 and U251 cell lines
  • Concentrations: 10 μM
  • Incubation Time: 5 days
  • Method: Cell cultures are harvested with 0.05% trypsin and seeded in triplicate at 2 × 104 in 24-well culture plates for 24 h before drug treatment. Culture medium is used for mock treatment. Cells are harvested at the indicated day after treatment, and viable cells are counted using the Vi-cell viability analyze
Animal Research:[1]
  • Animal Models: Male nude mice bearing intracranial glioma xenografts
  • Dosages: 75 mg/kg
  • Administration: Administered via oral gavage

Solubility (25°C)

In vitro

DMSO 94 mg/mL
(200.45 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% methylcellulose
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 468.94


CAS No. 761437-28-9
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy TAE226 (NVP-TAE226) | TAE226 (NVP-TAE226) supplier | purchase TAE226 (NVP-TAE226) | TAE226 (NVP-TAE226) cost | TAE226 (NVP-TAE226) manufacturer | order TAE226 (NVP-TAE226) | TAE226 (NVP-TAE226) distributor